The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

Authors

Jérémy Manry
Paul Bastard
Adrian Gervais
Tom Le Voyer
Jérémie Rosain
Quentin Philippot
Eleftherios Michailidis
Hans-Heinrich Hoffmann
Shohei Eto
Marina Garcia-Prat
Lucy Bizien
Alba Parra-Martínez
Rui Yang
Liis Haljasmägi
Mélanie Migaud
Karita Särekannu
Julia Maslovskaja
Nicolas de Prost
Yacine Tandjaoui-Lambiotte
Charles-Edouard Luyt
Blanca Amador-Borrero
Alexandre Gaudet
Julien Poissy
Pascal Morel
Pascale Richard
Fabrice Cognasse
Jesús Troya
Sophie Trouillet-Assant
Alexandre Belot
Kahina Saker
Pierre Garçon
Jacques G Rivière
Jean-Christophe Lagier
Stéphanie Gentile
Lindsey B Rosen
Elana Shaw
Tomohiro Morio
Junko Tanaka
David Dalmau
Pierre-Louis Tharaux
Damien Sene
Alain Stepanian
Bruno Mégarbane
Vasiliki Triantafyllia
Arnaud Fekkar
James R Heath, Institute for Systems Biology, Seattle, WA 98109Follow
José Luis Franco
Juan-Manuel Anaya
Jordi Solé-Violán
Luisa Imberti
Andrea Biondi
Paolo Bonfanti
Riccardo Castagnoli
Ottavia M Delmonte
Yu Zhang
Andrew L Snow
Steven M Holland
Catherine M Biggs
Marcela Moncada-Vélez
Andrés Augusto Arias
Lazaro Lorenzo
Soraya Boucherit
Dany Anglicheau
Anna M Planas
Filomeen Haerynck
Sotirija Duvlis
Tayfun Ozcelik
Sevgi Keles
Ahmed A Bousfiha
Jalila El Bakkouri
Carolina Ramirez-Santana
Stéphane Paul
Qiang Pan-Hammarström
Lennart Hammarström
Annabelle Dupont
Alina Kurolap
Christine N Metz
Alessandro Aiuti
Giorgio Casari
Vito Lampasona
Fabio Ciceri
Lucila A Barreiros
Elena Dominguez-Garrido
Mateus Vidigal
Mayana Zatz
Diederik van de Beek
Sabina Sahanic
Ivan Tancevski
Yurii Stepanovskyy
Oksana Boyarchuk
Yoko Nukui
Miyuki Tsumura
Loreto Vidaur
Stuart G Tangye
Sonia Burrel
Darragh Duffy
Lluis Quintana-Murci
Adam Klocperk
Nelli Y Kann
Anna Shcherbina
Yu-Lung Lau
Daniel Leung
Matthieu Coulongeat
Julien Marlet
Rutger Koning
Luis Felipe Reyes
Angélique Chauvineau-Grenier
Fabienne Venet
Guillaume Monneret
Michel C Nussenzweig
Romain Arrestier
Idris Boudhabhay
Hagit Baris-Feldman
David Hagin
Joost Wauters
Isabelle Meyts
Adam H Dyer
Sean P Kennelly
Nollaig M Bourke
Rabih Halwani
Fatemeh Saheb Sharif-Askari
Karim Dorgham
Jérôme Sallette
Souad Mehlal Sedkaoui
Suzan AlKhater
Raúl Rigo-Bonnin
Francisco Morandeira
Lucie Roussel
Donald C Vinh
Christian Erikstrup
Antonio Condino-Neto
Carolina Prando
Anastasiia Bondarenko
András N Spaan
Laurent Gilardin
Jacques Fellay
Stanislas Lyonnet
Kaya Bilguvar
Richard P Lifton
Shrikant Mane
Mark S Anderson
Bertrand Boisson
Vivien Béziat
Shen-Ying Zhang
Evangelos Andreakos
Olivier Hermine
Aurora Pujol
Pärt Peterson
Trine H Mogensen
Lee Rowen, Institute for Systems Biology, Seattle, WA 98109
James Mond
Stéphanie Debette
Xavier de Lamballerie
Charles Burdet
Lila Bouadma
Marie Zins
Pere Soler-Palacin
Roger Colobran
Guy Gorochov
Xavier Solanich
Sophie Susen
Javier Martinez-Picado
Didier Raoult
Marc Vasse
Peter K Gregersen
Lorenzo Piemonti
Carlos Rodríguez-Gallego
Luigi D Notarangelo
Helen C Su
Kai Kisand
Satoshi Okada
Anne Puel
Emmanuelle Jouanguy
Charles M Rice
Pierre Tiberghien
Qian Zhang
Jean-Laurent Casanova
Laurent Abel
Aurélie Cobat

Document Type

Article

Publication Date

5-24-2022

Publication Title

Proceedings of the National Academy of Sciences of the United States of America

Keywords

washington; isb; genomics; covid-19; COVID-19; autoantibodies; infection fatality rate; relative risk; type I IFNs; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Neutralizing; Autoantibodies; Autoimmunity; COVID-19; Female; Humans; Interferon Type I; Male; Middle Aged; Risk; SARS-CoV-2

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.

Department

Institute for Systems Biology

Department

Infectious Diseases

Share

COinS